Sp27

LEVERAGING SOCIAL MEDIA: BUILDING COMMUNITY FOR PRACTIONERS AND REACHING THE UNDERSERVED

Date
May 6, 2023
Explore related products in the following collection:

Society: AGA

The use of technology has expanded rapidly in clinical care and research in gastroenterology. Telehealth has improved access to care and transformed the ability to monitor patients from the safety of their own homes. Artificial intelligence has improved our predictive models and diagnostic capabilities. Social media is emerging as a tool to reach populations previously unengaged by health care. Despite these promising advances, disparities are increasingly being recognized in the creation, implementation, and use of these technologies. In this session, we will highlight disparities within telehealth and artificial intelligence/machine learning, but also outline evidence-based methods to promote equity within these disciplines. We will also discuss the role of social media in creating diverse communities for practitioners, advocates, and patients, and review how social media has facilitated outreach to vulnerable communities.

Presenter

Speaker Image for Patricia Bloom
University of Michigan

Tracks

Related Products

Thumbnail for INTRODUCTION
INTRODUCTION
SOCIETY: AGA
Thumbnail for MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for PANEL DISCUSSION
PANEL DISCUSSION
The use of technology has expanded rapidly in clinical care and research in gastroenterology. Telehealth has improved access to care and transformed the ability to monitor patients from the safety of their own homes…